Float Short %

19.58

Margin Of Safety %

Put/Call OI Ratio

0.51

EPS Next Q Diff

EPS Last/This Y

1.45

EPS This/Next Y

1.29

Price

9.2

Target Price

33.67

Analyst Recom

1.8

Performance Q

115.89

Relative Volume

0.7

Beta

2.47

Ticker: OMER

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-17	OMER	9.08	0.51	0.13	110023
2025-11-18	OMER	8.48	0.52	0.42	110047
2025-11-19	OMER	8.2	0.52	0.21	126992
2025-11-20	OMER	8.22	0.51	0.19	129811
2025-11-21	OMER	8.88	0.50	0.06	134808
2025-11-24	OMER	9.77	0.44	0.20	99581
2025-11-25	OMER	9.45	0.44	0.05	102956
2025-11-26	OMER	9.64	0.44	0.57	103272
2025-12-01	OMER	9.68	0.45	1.00	103994
2025-12-02	OMER	9.42	0.47	0.46	106101
2025-12-03	OMER	10.63	0.47	0.22	107002
2025-12-04	OMER	11.02	0.47	0.30	107648
2025-12-05	OMER	10.85	0.48	0.39	107436
2025-12-08	OMER	11.4	0.48	0.17	108526
2025-12-09	OMER	11.45	0.48	0.11	109733
2025-12-10	OMER	11.24	0.48	0.80	112204
2025-12-11	OMER	10.55	0.50	0.48	116893
2025-12-12	OMER	10.17	0.51	0.12	119449
2025-12-15	OMER	9.21	0.50	0.48	120446
2025-12-16	OMER	8.77	0.51	0.97	120972
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-17	OMER	9.09	7.7	-	-2.02
2025-11-18	OMER	8.48	7.7	-	-1.25
2025-11-19	OMER	8.22	7.7	-	-1.25
2025-11-20	OMER	8.23	7.7	-	-1.25
2025-11-21	OMER	8.87	129.6	-	-1.25
2025-11-24	OMER	9.77	129.6	-	-1.25
2025-11-25	OMER	9.45	129.6	-	-1.25
2025-11-26	OMER	9.63	129.6	-	-1.25
2025-12-01	OMER	9.68	129.6	-	-1.25
2025-12-02	OMER	9.43	129.6	-	-1.25
2025-12-03	OMER	10.62	129.6	-	-1.25
2025-12-04	OMER	11.02	129.6	-	-1.25
2025-12-05	OMER	10.85	129.6	-	-1.25
2025-12-08	OMER	11.40	129.6	-	-1.25
2025-12-09	OMER	11.47	129.6	-	-1.25
2025-12-10	OMER	11.25	129.6	-	-1.25
2025-12-11	OMER	10.58	129.6	-	-1.25
2025-12-12	OMER	10.15	129.6	-	-1.25
2025-12-15	OMER	9.20	129.6	-	-1.25
2025-12-16	OMER	9.20	129.6	-	-1.25
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-17	OMER	0.00	6.26	0
2025-11-18	OMER	0.00	6.26	17.85
2025-11-19	OMER	0.00	6.26	17.85
2025-11-20	OMER	0.00	6.26	17.85
2025-11-21	OMER	0.00	6.26	17.85
2025-11-24	OMER	0.00	6.18	17.85
2025-11-25	OMER	0.00	6.18	17.85
2025-11-26	OMER	0.00	6.18	19.61
2025-12-01	OMER	0.00	6.17	19.61
2025-12-02	OMER	0.00	6.17	19.61
2025-12-03	OMER	0.00	6.17	19.61
2025-12-04	OMER	0.00	6.17	19.61
2025-12-05	OMER	0.00	6.17	19.61
2025-12-08	OMER	0.00	6.18	19.61
2025-12-09	OMER	0.00	6.18	19.61
2025-12-10	OMER	0.00	6.18	19.61
2025-12-11	OMER	0.00	6.18	19.61
2025-12-12	OMER	0.00	6.18	19.61
2025-12-15	OMER	0.00	6.18	19.58
2025-12-16	OMER	0.00	6.18	19.58
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.19

Avg. EPS Est. Current Quarter

0.16

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

6.18

Beta

2.47

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

61.4

Max Drawdown 5-Year %

-95.4

Target Price

33.67

P/E

Forward P/E

206.24

PEG

P/S

P/B

P/Free Cash Flow

EPS

-2.02

Average EPS Est. Cur. Y

-1.25

EPS Next Y. (Est.)

0.04

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.7

Return on Equity vs Sector %

27.8

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

0.76

EBIT Estimation

Omeros Corporation

Sector: Healthcare

Industry: Biotechnology

Employees: 202

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

stock quote shares OMER – Omeros Corporation Stock Price stock today

news today OMER – Omeros Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch OMER – Omeros Corporation yahoo finance google finance

stock history OMER – Omeros Corporation invest stock market

stock prices OMER premarket after hours

ticker OMER fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: OMER

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y